Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients

NCT03927144 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

621

Enrollment

INDUSTRY

Sponsor class

Conditions

Episodic Migraine

Interventions

DRUG: AMG334
DRUG: Oral Prophylactic

Sponsor

Amgen

Collaborators

[object Object]